Kenneth R Cooke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11915280/publications.pdf

Version: 2024-02-01

128 papers 8,447 citations

51 h-index 89 g-index

132 all docs

132 docs citations

times ranked

132

7433 citing authors

#	Article	IF	CITATIONS
1	Pulmonary surveillance in pediatric hematopoietic stem cell transplant: A multinational multidisciplinary survey. Cancer Reports, 2022, 5, e1501.	0.6	5
2	Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort. Bone Marrow Transplantation, 2022, 57, 279-281.	1.3	2
3	Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood, 2022, 139, 608-623.	0.6	42
4	Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight, 2022, 7, .	2.3	12
5	A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation. Blood Advances, 2022, 6, 1866-1878.	2.5	4
6	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 2022, 6, 2520-2534.	2.5	19
7	Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. Journal of Clinical Investigation, 2022, 132, .	3.9	4
8	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. Annals of the American Thoracic Society, 2021, 18, 381-394.	1.5	26
9	Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. Journal of Clinical Immunology, 2021, 41, 414-426.	2.0	12
10	Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. Stem Cells, 2021, 39, 1506-1519.	1.4	4
11	Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood, 2020, 135, 1428-1437.	0.6	15
12	Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience. Pediatric Blood and Cancer, 2020, 67, e28403.	0.8	22
13	Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. British Journal of Haematology, 2020, 190, 822-836.	1.2	53
14	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2020, 26, e94-e100.	2.0	3
15	Cryo-imaging of Stem Cell Biodistribution in Mouse Model of Graft-Versus-Host-Disease. Annals of Biomedical Engineering, 2020, 48, 1702-1711.	1.3	11
16	Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplantation, 2019, 54, 383-392.	1.3	30
17	Chemokines and Graft-Versus-Host Disease. , 2019, , 323-347.		0
18	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematology,the, 2019, 6, e183-e193.	2.2	111

#	Article	IF	Citations
19	Noninfectious Pulmonary Complications. , 2019, , 393-401.		7
20	The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation. Pediatric Transplantation, 2018, 22, e13139.	0.5	17
21	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028.	2.0	29
22	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
23	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.4	47
24	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064.	2.0	32
25	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2017, 23, 612-617.	2.0	17
26	Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice. Blood, 2017, 129, 246-256.	0.6	14
27	Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica, 2017, 102, 932-940.	1.7	27
28	Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1. Pediatric Critical Care Medicine, 2017, 18, S50-S57.	0.2	17
29	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood, 2017, 129, 1389-1393.	0.6	69
30	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 2127-2136.	2.0	17
31	Tolerance and effectiveness of nivolumab after pediatric Tâ€eell replete, haploidentical, bone marrow transplantation: A case report. Pediatric Blood and Cancer, 2017, 64, e26257.	0.8	22
32	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 211-234.	2.0	328
33	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 325-332.	2.0	61
34	Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. Biology of Blood and Marrow Transplantation, 2016, 22, 895-901.	2.0	64
35	Automatic Stem Cell Detection in Microscopic Whole Mouse Cryo-Imaging. IEEE Transactions on Medical Imaging, 2016, 35, 819-829.	5.4	20
36	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen–Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 112-118.	2.0	37

3

#	Article	IF	CITATIONS
37	Idiopathic pneumonia syndrome following hematopoietic stem cell transplantation. Journal of Pediatric Intensive Care, 2015, 03, 147-157.	0.4	8
38	Lung parenchyma-derived IL-6 promotes IL-17A–dependent acute lung injury after allogeneic stem cell transplantation. Blood, 2015, 125, 2435-2444.	0.6	73
39	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 780-792.	2.0	124
40	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1251-1257.	2.0	14
41	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1479-1487.	2.0	173
42	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1046-1053.	2.0	133
43	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biology of Blood and Marrow Transplantation, 2015, 21, 67-73.	2.0	62
44	Human Mesenchymal Stromal Cells Attenuate Graft-Versus-Host Disease and Maintain Graft-Versus-Leukemia Activity Following Experimental Allogeneic Bone Marrow Transplantation. Stem Cells, 2015, 33, 601-614.	1.4	76
45	Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA). Blood, 2015, 126, 2031-2031.	0.6	14
46	Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation. Journal of Stem Cells and Regenerative Medicine, 2015, 11, 34-43.	2.2	6
47	A "Window of Opportunity―for Patients with Late-Onset Pulmonary Dysfunction after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 291-292.	2.0	10
48	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. Biology of Blood and Marrow Transplantation, 2014, 20, 858-864.	2.0	78
49	Novel T lymphocyte proliferation assessment using whole mouse cryo-imaging. Proceedings of SPIE, 2014, , .	0.8	3
50	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. Pediatric Oncology, 2014, , 77-102.	0.5	1
51	Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study. Biology of Blood and Marrow Transplantation, 2013, 19, S169.	2.0	4
52	Chemokines and graft-versus-host disease. , 2013, , 393-424.		6
53	Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood, 2013, 122, 3871-3878.	0.6	141
54	Human Biomarker Discovery and Predictive Models for Disease Progression for Idiopathic Pneumonia Syndrome Following Allogeneic Stem Cell Transplantation. Molecular and Cellular Proteomics, 2012, 11, M111.015479.	2.5	37

#	Article	IF	CITATIONS
55	National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines. Biology of Blood and Marrow Transplantation, 2012, 18, 334-347.	2.0	82
56	Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1044-1054.	2.0	48
57	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2012, 120, 733-733.	0.6	4
58	Comorbidity Index (CI) in Autologous Hematopoietic Cell Transplantation (HCT) for Malignant Diseases: Validation of the HCT-CI. Blood, 2012, 120, 814-814.	0.6	10
59	The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases. Blood, 2012, 120, 737-737.	0.6	11
60	The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation. Blood, 2012, 120, 762-762.	0.6	1
61	Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications. Biology of Blood and Marrow Transplantation, 2011, 17, S101-S108.	2.0	5
62	National Cancer Institute–National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Long-Term Organ Damage and Dysfunction. Biology of Blood and Marrow Transplantation, 2011, 17, 1573-1584.	2.0	76
63	An Official American Thoracic Society Research Statement: Noninfectious Lung Injury after Hematopoietic Stem Cell Transplantation: Idiopathic Pneumonia Syndrome. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1262-1279.	2.5	271
64	Charlson Comorbidity Index (CCI) Not Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Successfully Predicts Transplant Related Mortality and Post-Transplant Outcomes in Elderly Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. Blood, 2011, 118, 3006-3006.	0.6	0
65	A role for lymphotoxin in GVHD and GVL. Blood, 2010, 115, 3-4.	0.6	2
66	Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. Journal of Experimental Medicine, 2010, 207, 2507-2519.	4.2	60
67	Regenerative Stromal Cell Therapy in Allogeneic Hematopoietic Stem Cell Transplantation: Current Impact and Future Directions. Biology of Blood and Marrow Transplantation, 2010, 16, 891-906.	2.0	39
68	Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation: A shifting Paradigm for T Cell Allo-activation. Biology of Blood and Marrow Transplantation, 2010, 16, 598-611.	2.0	16
69	Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Blood, 2010, 116, 3486-3486.	0.6	2
70	Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. Journal of Cell Biology, 2010, 191, i4-i4.	2.3	0
71	Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration. Blood Purification, 2009, 28, 348-353.	0.9	2
72	Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. Current Opinion in Pediatrics, 2009, 21, 30-38.	1.0	23

#	Article	IF	CITATIONS
73	A biomarker panel for acute graft-versus-host disease. Blood, 2009, 113, 273-278.	0.6	348
74	Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes Blood, 2009, 114, 43-43.	0.6	0
75	The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation. Pediatric Blood and Cancer, 2008, 50, 911-914.	0.8	6
76	The Contribution of Endothelial Activation and Injury to End-Organ Toxicity following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 23-32.	2.0	79
77	A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome. Biology of Blood and Marrow Transplantation, 2008, 14, 385-396.	2.0	21
78	The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood, 2008, 112, 3073-3081.	0.6	117
79	Lung Injury after Hematopoietic Stem Cell Transplantation. , 2008, , 495-536.		0
80	CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood, 2007, 110, 3447-3455.	0.6	76
81	Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 749-759.	2.0	170
82	Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. Experimental Hematology, 2007, 35, 155-163.	0.2	19
83	The Lung as a Target Organ of Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 42-52.	1.8	57
84	Pulmonary toxicity following hematopoietic cell transplantation: Is the lung a target organ of graft-versus-host disease?. Current Opinion in Organ Transplantation, 2006, 11 , $69-77$.	0.8	4
85	Critical Role of Prostaglandin E2 Overproduction in Impaired Pulmonary Host Response following Bone Marrow Transplantation. Journal of Immunology, 2006, 177, 5499-5508.	0.4	78
86	Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM Blood, 2006, 108, 37-37.	0.6	1
87	A Role for CD54 (Intercellular Adhesion Molecule-1) in Leukocyte Recruitment to the Lung During the Development of Experimental Idiopathic Pneumonia Syndrome. Transplantation, 2005, 79, 536-542.	0.5	21
88	Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood, 2005, 105, 2249-2257.	0.6	44
89	Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again. Pediatric Transplantation, 2005, 9, 25-36.	0.5	29
90	Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2005, 11, 680-687.	2.0	89

#	Article	IF	Citations
91	Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation Blood, 2005, 106, 3107-3107.	0.6	0
92	Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease. Journal of Immunology, 2004, 172, 7393-7398.	0.4	225
93	Blockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia Syndrome. Journal of Immunology, 2004, 173, 2050-2059.	0.4	95
94	Graft-versus-host disease of the skin: life and death on the epidermal edge. Biology of Blood and Marrow Transplantation, 2004, 10, 366-372.	2.0	34
95	Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 461-472.	2.0	34
96	A Role for Tumor Necrosis Factor-α-Mediated Endothelial Apoptosis in the Development of Experimental Idiopathic Pneumonia Syndrome. Transplantation, 2004, 78, 494-502.	0.5	53
97	A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 2004, 103, 2417-2426.	0.6	86
98	Donor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 2004, 104, 586-593.	0.6	85
99	Survival Following Etanercept Therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem Cell Transplantation Blood, 2004, 104, 354-354.	0.6	5
100	Pathophysiology of Lung Injury After Hematopoietic Stem Cell Transplantation., 2004,, 271-295.		0
101	The Use of Laparoscopic Liver Biopsies in Pediatric Patients with Hepatic Dysfunction Following Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2004, 104, 1147-1147.	0.6	0
102	IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease? Blood, 2004, 104, 3070-3070.	0.6	0
103	CCR1 Expression on Donor Leukocytes Is Critical to the Development of Graft Versus Host Disease after Allogeneic SCT Blood, 2004, 104, 3067-3067.	0.6	0
104	The Pathophysiology of Acute Graft-versus-Host Disease. International Journal of Hematology, 2003, 78, 181-187.	0.7	185
105	Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology, 2003, 31, 897-902.	0.2	152
106	Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Biology of Blood and Marrow Transplantation, 2003, 9, 592-603.	2.0	19
107	Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood, 2003, 101, 2877-2885.	0.6	65
108	Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood, 2003, 102, 429-435.	0.6	97

7

#	Article	IF	CITATIONS
109	Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8î±+ dendritic cells and reduces experimental acute graft-versus-host disease. Blood, 2002, 99, 1825-1832.	0.6	72
110	Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood, 2002, 100, 3429-3431.	0.6	37
111	Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 395-400.	2.0	117
112	Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine, 2002, 8, 575-581.	15.2	495
113	The role of endotoxin and the innate immune response in the pathophysiology of acute graft <1>versus 1 host disease. Journal of Endotoxin Research, 2002, 8, 441-448.	2.5	65
114	LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. Journal of Clinical Investigation, 2001, 107, 1581-1589.	3.9	258
115	Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation. Journal of Immunology, 2000, 165, 6612-6619.	0.4	73
116	The p55 TNF-α Receptor Plays a Critical Role in T Cell Alloreactivity. Journal of Immunology, 2000, 164, 656-663.	0.4	130
117	TUMOR NECROSIS FACTOR-?? NEUTRALIZATION REDUCES LUNG INJURY AFTER EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION1. Transplantation, 2000, 70, 272-279.	0.5	120
118	Granulocyte Colony-Stimulating Factor–Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. Blood, 1999, 93, 4071-4078.	0.6	108
119	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. Blood, 1999, 94, 825-831.	0.6	168
120	PRETRANSPLANT CHEMOTHERAPY REDUCES INFLAMMATORY CYTOKINE PRODUCTION AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1999, 67, 1478-1480.	0.5	25
121	Differential roles of IL-1 and TNF- \hat{l}_{\pm} on graft-versus-host disease and graft versus leukemia. Journal of Clinical Investigation, 1999, 104, 459-467.	3.9	229
122	IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. Journal of Clinical Investigation, 1999, 104, 317-325.	3.9	159
123	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. Blood, 1999, 94, 825-831.	0.6	8
124	Host Reactive Donor T Cells Are Associated With Lung Injury After Experimental Allogeneic Bone Marrow Transplantation. Blood, 1998, 92, 2571-2580.	0.6	114
125	Host Reactive Donor T Cells Are Associated With Lung Injury After Experimental Allogeneic Bone Marrow Transplantation. Blood, 1998, 92, 2571-2580.	0.6	18
126	Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines. Blood, 1997, 90, 3204-3213.	0.6	765

#	Article	IF	CITATIONS
127	The Immunopathophysiology of Acute Graftâ€Versusâ€Hostâ€Disease. Stem Cells, 1996, 14, 473-489.	1.4	185
128	TRANSPLANTATION OF POLARIZED TYPE 2 DONOR T CELLS REDUCES MORTALITY CAUSED BY EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE1. Transplantation, 1996, 62, 1278-1285.	0.5	57